Photo by oraly from unsplash
Rybelsus (semaglutide) is the first GLP‐1 agonist for the treatment of type 2 diabetes to be available as an oral formulation. This article discusses its properties, efficacy and adverse effects. Click to show full abstract
Rybelsus (semaglutide) is the first GLP‐1 agonist for the treatment of type 2 diabetes to be available as an oral formulation. This article discusses its properties, efficacy and adverse effects.
Keywords:
rybelsus oral;
agonist semaglutide;
formulation glp;
glp agonist;
oral formulation
Journal Title: Prescriber
Year Published: 2020
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Prescriber
Year Published: 2020
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!